While it has no significant tumor suppressive effect as a single agent, GSK2801 showed a strong synergistic activity along with the BET inhibitor JQ1 in several TNBC cell lines by targeting BRD2 (Bromodomain-containing protein 2), which is co-regulated along with BAZ2A/B (Bevill et al., 2019). Here, BRD2 is linked to neoplasm.